An Overview on the Field of Micro- and Nanotechnologies for Synthetic Peptide-Based Vaccines

18 p.

Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research

There is no malaria vaccine currently available, and the most advanced candidate has recently reported a modest 30% efficacy against clinical malaria. Although many efforts have been dedicated to achieve this goal, the research was mainly directed to identify antigenic targets. Nevertheless, the latest progresses on understanding how immune system works and the data recovered from vaccination studies have conferred to the vaccine formulation its deserved relevance. Additionally to the antigen nature, the manner in which it is presented (delivery adjuvants) as well as the immunostimulatory effect of the formulation components (immunostimulants) modulates the immune response elicited. Protective immunity against malaria requires the induction of humoral, antibody-dependent cellular inhibition (ADCI) and effector and memory cell responses. This review summarizes the status of adjuvants that have been or are being employed in the malaria vaccine development, focusing on the pharmaceutical and immunological aspects, as well as on their immunization outcomings at clinical and preclinical stages.

The radio is dead. Long live the radio : Leioan, 2011ko azaroaren 24 eta 25ean egindako Ikus-Entzunezko Komunikazioa eta Publizitateko Nazioarteko I. Kongresuaren aktak

A menudo, el deslumbramiento de los nuevos medios impide el reconocimiento debido a otras alternativas de comunicación social que, de manera persistente y discreta, han llegado a confundirse con nuestra propia vida. Es el caso de este medio invisible, que bien se merecía un congreso dedicado a la mejor radio y a uno de sus mayores inspiradores, Bertolt Brecht, quien ochenta años atrás imaginó una radio interactiva cuando no existía la tecnología necesaria para hacer realidad su sueño. Hoy como ayer, las voces comunicantes de la radio cuentan mil y una historias que los oyentes siguen como si les fuera la vida en ello. Quizá la radio no esté a la cabeza de las industrias creativas, pero su magia sigue desatando la imaginación y la creatividad de las audiencias. Es por eso, y por su cercanía, que da tanta confianza y es tan querida. Nada más lejos de nuestra intención que la autocomplacencia, un virus tanto o más peligroso que el ruido y la cacofonía radiofónica, que de todo hay en el dial. Los participantes en este encuentro nos hemos conjurado a favor de una radio abierta; hecha con cabeza y corazón, como la vida misma; y más acogedora con los jóvenes creadores, que no lo saben todo de la radio, pero, por eso mismo, están mejor preparados para llevar el ritmo que bailan las neuronas de las nuevas audiencias. Una radio que da la palabra a la gente, sabe escuchar, y no se agota en el ejercicio inútil de escucharse a sí misma.

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero (R)) in Gipuzkoa, Northern Spain

The effectiveness of a vaccine is determined not only by the immunogenicity of its components, but especially by how widely it covers the disease-causing strains circulating in a given region. Because vaccine coverage varies over time, this study aimed to detect possible changes that could affect vaccine protection during a specific period in a southern European region. The 4CMenB vaccine is licensed for use in Europe, Canada, and Australia and is mainly directed against Neisseria meningitidis serogroup B. This vaccine contains four main immunogenic components: three recombinant proteins, FHbp, Nhba and NadA, and an outer membrane vesicle [PorA P1.4]. The allelic distribution of FHbp, Nhba, NadA, and PorA antigens in 82 invasive isolates (B and non-B serogroups) isolated from January 2008 to December 2013 were analyzed. 4CMenB was likely protective against 61.8% and 50% of serogroup B and non-B meningococci, respectively, in the entire period, but between 2012 and 2013, the predicted protection fell below 45% (42.1% for serogroup B isolates). The observed decreasing trend in the predicted protection during the 6 years of the study (X-2 for trend = 4.68, p=0.03) coincided with a progressive decrease of several clonal complexes (e. g., cc11, cc32 and cc41/44), which had one or more antigens against which the vaccine would offer protection.